Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Net Cash Flow (2016 - 2025)

Avanos Medical's Net Cash Flow history spans 11 years, with the latest figure at $22.9 million for Q4 2024.

  • For Q4 2024, Net Cash Flow rose 209.05% year-over-year to $22.9 million; the TTM value through Dec 2024 reached $24.1 million, up 159.95%, while the annual FY2025 figure was -$22.9 million, 195.02% down from the prior year.
  • Net Cash Flow for Q4 2024 was $22.9 million at Avanos Medical, up from -$5.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $26.9 million in Q3 2023 and bottomed at -$72.3 million in Q4 2020.
  • The 5-year median for Net Cash Flow is -$5.2 million (2020), against an average of -$4.5 million.
  • The largest annual shift saw Net Cash Flow plummeted 551.35% in 2020 before it surged 1787.5% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$72.3 million in 2020, then surged by 129.88% to $21.6 million in 2021, then tumbled by 68.06% to $6.9 million in 2022, then tumbled by 404.35% to -$21.0 million in 2023, then surged by 209.05% to $22.9 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Net Cash Flow are $22.9 million (Q4 2024), -$5.0 million (Q3 2024), and $16.9 million (Q2 2024).